Details
Stereochemistry | RACEMIC |
Molecular Formula | C10H17NO2 |
Molecular Weight | 183.2475 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1(CC)C(=O)NCC(C)C1=O
InChI
InChIKey=SIDLZWOQUZRBRU-UHFFFAOYSA-N
InChI=1S/C10H17NO2/c1-4-10(5-2)8(12)7(3)6-11-9(10)13/h7H,4-6H2,1-3H3,(H,11,13)
DescriptionSources: https://www.drugs.com/mmx/methyprylon.html
Sources: https://www.drugs.com/mmx/methyprylon.html
Methyprylon (brand name Noludar) is a sedative agent, which used to treat insomnia. But then the drug was replaced in the market by another drugs with less side effects. The precise mechanism of action is not known, but was made suggestion, that methyprylon increases the effects of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the brain.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16792 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | NOLUDAR Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.62 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2866242 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
METHYPRYLON plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
74.75 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2866242 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
METHYPRYLON plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
9.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2866242 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
METHYPRYLON plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
30 g single, oral Overdose Dose: 30 g Route: oral Route: single Dose: 30 g Co-administed with:: dimenhydrinate(one hundred 50-mg capsules) Sources: |
unhealthy, 36 years n = 1 Health Status: unhealthy Age Group: 36 years Sex: F Population Size: 1 Sources: |
Other AEs: Comatose... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Comatose | 1 patient | 30 g single, oral Overdose Dose: 30 g Route: oral Route: single Dose: 30 g Co-administed with:: dimenhydrinate(one hundred 50-mg capsules) Sources: |
unhealthy, 36 years n = 1 Health Status: unhealthy Age Group: 36 years Sex: F Population Size: 1 Sources: |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16792
300 mg once a day before bedtime.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN05CE02
Created by
admin on Fri Dec 15 16:31:08 GMT 2023 , Edited by admin on Fri Dec 15 16:31:08 GMT 2023
|
||
|
NCI_THESAURUS |
C29756
Created by
admin on Fri Dec 15 16:31:08 GMT 2023 , Edited by admin on Fri Dec 15 16:31:08 GMT 2023
|
||
|
DEA NO. |
2575
Created by
admin on Fri Dec 15 16:31:08 GMT 2023 , Edited by admin on Fri Dec 15 16:31:08 GMT 2023
|
||
|
WHO-ATC |
N05CE02
Created by
admin on Fri Dec 15 16:31:08 GMT 2023 , Edited by admin on Fri Dec 15 16:31:08 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6910
Created by
admin on Fri Dec 15 16:31:08 GMT 2023 , Edited by admin on Fri Dec 15 16:31:08 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID7023306
Created by
admin on Fri Dec 15 16:31:08 GMT 2023 , Edited by admin on Fri Dec 15 16:31:08 GMT 2023
|
PRIMARY | |||
|
3128
Created by
admin on Fri Dec 15 16:31:08 GMT 2023 , Edited by admin on Fri Dec 15 16:31:08 GMT 2023
|
PRIMARY | |||
|
C66122
Created by
admin on Fri Dec 15 16:31:08 GMT 2023 , Edited by admin on Fri Dec 15 16:31:08 GMT 2023
|
PRIMARY | |||
|
30442
Created by
admin on Fri Dec 15 16:31:08 GMT 2023 , Edited by admin on Fri Dec 15 16:31:08 GMT 2023
|
PRIMARY | |||
|
4162
Created by
admin on Fri Dec 15 16:31:08 GMT 2023 , Edited by admin on Fri Dec 15 16:31:08 GMT 2023
|
PRIMARY | |||
|
287
Created by
admin on Fri Dec 15 16:31:08 GMT 2023 , Edited by admin on Fri Dec 15 16:31:08 GMT 2023
|
PRIMARY | |||
|
METHYPRYLON
Created by
admin on Fri Dec 15 16:31:08 GMT 2023 , Edited by admin on Fri Dec 15 16:31:08 GMT 2023
|
PRIMARY | |||
|
SUB08879MIG
Created by
admin on Fri Dec 15 16:31:08 GMT 2023 , Edited by admin on Fri Dec 15 16:31:08 GMT 2023
|
PRIMARY | |||
|
CHEMBL1200790
Created by
admin on Fri Dec 15 16:31:08 GMT 2023 , Edited by admin on Fri Dec 15 16:31:08 GMT 2023
|
PRIMARY | |||
|
1774
Created by
admin on Fri Dec 15 16:31:08 GMT 2023 , Edited by admin on Fri Dec 15 16:31:08 GMT 2023
|
PRIMARY | |||
|
DB01107
Created by
admin on Fri Dec 15 16:31:08 GMT 2023 , Edited by admin on Fri Dec 15 16:31:08 GMT 2023
|
PRIMARY | |||
|
204-745-4
Created by
admin on Fri Dec 15 16:31:08 GMT 2023 , Edited by admin on Fri Dec 15 16:31:08 GMT 2023
|
PRIMARY | |||
|
m7482
Created by
admin on Fri Dec 15 16:31:08 GMT 2023 , Edited by admin on Fri Dec 15 16:31:08 GMT 2023
|
PRIMARY | Merck Index | ||
|
7238
Created by
admin on Fri Dec 15 16:31:08 GMT 2023 , Edited by admin on Fri Dec 15 16:31:08 GMT 2023
|
PRIMARY | |||
|
125-64-4
Created by
admin on Fri Dec 15 16:31:08 GMT 2023 , Edited by admin on Fri Dec 15 16:31:08 GMT 2023
|
PRIMARY | |||
|
100000080891
Created by
admin on Fri Dec 15 16:31:08 GMT 2023 , Edited by admin on Fri Dec 15 16:31:08 GMT 2023
|
PRIMARY | |||
|
CUT48I42ON
Created by
admin on Fri Dec 15 16:31:08 GMT 2023 , Edited by admin on Fri Dec 15 16:31:08 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)